GLP-1 & Metabolic Peptides Compounds
Semaglutide
(GLP-1 Receptor Agonist)The GLP-1 agonist characterized across the landmark STEP Phase III trial program
MW:4113.58 Da
AA:31 residues
Half-life:~7 days (human, subcutaneous)
Purity:≥99% HPLC
Tirzepatide
(Dual GIP/GLP-1 Agonist)The dual incretin studied across the SURMOUNT Phase III trial program
MW:4813.48 Da
AA:39 residues
Half-life:~5 days (human, subcutaneous)
Purity:≥99% HPLC
Retatrutide
(GIP/GLP-1/Glucagon Triple Agonist)The investigational triple agonist studied in Phase II metabolic-endpoint trials
MW:4731.4 Da
AA:39 residues
Half-life:~6 days (human, subcutaneous)
Purity:≥99% HPLC